INT273003

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 5
Disease Relevance 3.27
Pain Relevance 0.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL33) extracellular region (IL33)
Anatomy Link Frequency
D17 1
skin 1
IL33 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 50 99.42 Very High Very High Very High
chemokine 12 90.92 High High
Pain 18 89.88 High High
Inflammatory response 4 76.16 Quite High
sNRI 39 74.96 Quite High
Duloxetine 36 51.36 Quite High
depression 42 12.00 Low Low
sSRI 42 5.00 Very Low Very Low Very Low
antidepressant 18 5.00 Very Low Very Low Very Low
Serotonin 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Eczema 62 99.84 Very High Very High Very High
INFLAMMATION 54 99.42 Very High Very High Very High
Anaphylaxis 2 99.36 Very High Very High Very High
Rhinitis 124 99.16 Very High Very High Very High
Disorder Of Lipid Metabolism 18 98.64 Very High Very High Very High
Cv Unclassified Under Development 9 97.68 Very High Very High Very High
Pain 18 89.88 High High
Asthma 37 89.52 High High
Polyps 26 79.08 Quite High
Depression 126 76.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Increased IL1RL1 transcription is also observed in AD (Table 2), and IL33 appears to be increased in AD skin and anaphylactic responses [32].
Positive_regulation (increased) of IL33 in skin associated with anaphylaxis and eczema
1) Confidence 0.26 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2897889 Disease Relevance 0.94 Pain Relevance 0.10
Additional transcription changes likely associated with Th2-like eosinophilic inflammation were prominent and included increased IL1RL1 (IL33 receptor) and EMR1&3 and decreased CRISP2&3.
Positive_regulation (increased) of IL33 associated with rhinitis and inflammation
2) Confidence 0.26 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2897889 Disease Relevance 1.55 Pain Relevance 0.23
In a third study, clinically important changes in laboratory tests were reported for 3 patients taking DVS 50 mg:35 1 subject had increased fasting glucose, 1 had increased total cholesterol, and 1 had elevated ALT/SGPT.
Positive_regulation (increased) of DVS associated with disorder of lipid metabolism
3) Confidence 0.08 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.27 Pain Relevance 0
There was a significantly greater reduction in HAM-D17 from baseline for both DVS 200 mg/day (?
Positive_regulation (was) of DVS in D17
4) Confidence 0.08 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.09 Pain Relevance 0.09
Although a statistically significant increase in QT and QTc interval for DVS treatment groups has been reported (exception Liebowitz33) that seems to be dose related, no patients had ECG abnormalites considered clinically relevant.


Positive_regulation (increase) of DVS
5) Confidence 0.08 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695227 Disease Relevance 0.42 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox